Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .
NCT02788006
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
43
Enrollment
OTHER
Sponsor class
Conditions
Colorectal Adenocarcinoma
Interventions
DRUG:
Regorafenib 160 mg
Sponsor
Federation Francophone de Cancerologie Digestive